Your Directors submit their report for the half-year ended 31 December 2012

DIRECTORS

The names and details of the Company's directors in office during the half-year and until the date of this report are as below. Directors were in office for this entire period unless otherwise stated.

Peter Terence Kempen
FCA, FAICD (Chairman)

Dr Sam Aaron Hupert
M.B.B.S. (Deputy Chairman and Chief Executive Officer)

Anthony Barry Hall
B.Sc.(Hons), M.Sc. (Executive Director and Technology Director)

Roderick Lyle
LL.B., B.Com, LL.M (Lond), MBA (Melb) (Non-Executive Director)

REVIEW AND RESULTS OF OPERATIONS

The Company reported a first half after tax profit of $4.76M, up 335.1% as compared to the same period last year.

The key driver of the profit increase was the sale of Amira business in July 2012 which generated a one-off after-tax profit of $8.45M. This was partially offset by a decrease in the carrying value of some of the company's intangible assets which resulted in an after-tax impairment loss of $3.22M.

The result from the underlying operations for the half year was a loss of $0.63m. This result was impacted by adverse foreign currency movements and additional costs, mainly associated with the introduction of Coral to the market. Revenue from continuing operations was $5.81M, down 2.3% period on period.

During the period the company continued its significant investment in R&D, both in Australia as well as overseas. This has led to a number of enhancements to the existing product lines as well as significant progress with the company's new technology RIS platform, which continued to be rolled out to new sites during the half.

Promedicus.net, the company's e-health offering, continued to perform well throughout the period despite increasing competition.

The company's cash reserves grew to $18.36 million at the end of December 2012. It is estimated that approximately $4.0M of this will be used to pay tax on the profit of the Amira sale, leaving the company with cash reserves of over $14M. The company remains debt free.

The Board is of the view that whilst difficult trading conditions in Europe and North America continue to provide challenges in the short to medium term, the company is now better placed to meet these challenges as they arise As a result the company has announced an interim dividend of 1.0c per share fully franked.

ROUNDING

The amounts contained in this report have been rounded to the nearest $1,000 (where rounding is applicable) under the option available to the company under ASIC Class Order 98/0100. The company is an entity to which Class Order applies.

AUDITORS' INDEPENDENCE DECLARATION

In accordance with section 307C of the Corporations Act 2001, we have obtained a declaration of independence from our auditors Ernst & Young, a copy of which is attached.

Signed in accordance with a resolution of the directors.

P T Kempen
Chairman
Melbourne, 22 February 2013

Ernst & Young Building
8 Exhibition Street
Melbourne VIC 3000 Australia
GPO Box 67 Melbourne VIC 3001

Tel: +61 3 9288 8000
Fax: +61 3 8650 7777
www.ey.com/au

Auditor's Independence Declaration to the Directors of Pro Medicus Limited

In relation to our review of the financial report of Pro Medicus Limited for the half-year ended 31 December 2012, to the best of my knowledge and belief, there have been no contraventions of the auditor independence requirements of the *Corporations Act 2001* or any applicable code of professional conduct.

Ernst & Young

Ernst & Young

David Petersen
Partner
Melbourne
22 February 2013

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 31 DECEMBER 2012	Notes	Consolidated 2012 $'000	2011 $'000
Continuing operations			
Revenue		**5,784**	5,926
Finance Revenue		**23**	20
Revenue		**5,807**	5,946
Cost of Sales		**(137)**	(156)
Gross Profit		**5,670**	5,790
Net Currency Gains/(Losses)		**(110)**	442
Accounting & Secretarial Fees		**(273)**	(241)
Advertising and Public Relations		**(453)**	(318)
Depreciation & Amortisation	3	**(1,542)**	(1,862)
Insurance		**(172)**	(158)
Legal Costs		**(36)**	(109)
Operating Lease Expenditure - minimum lease payments		**(168)**	(187)
Impairment Expense	8	**(4,600)**	-
Other Expense		**(223)**	(53)
Salaries and Employee Benefits Expense	3	**(2,961)**	(2,281)
Travel and Accommodation		**(238)**	(236)
Profit/(loss) for the period from continuing operations before tax		**(5,106)**	787
Income tax expense		**1,258**	(270)
Profit/(loss) for the period from continuing operations		**(3,848)**	517
Discontinued operations			
Profit/(loss) after tax for the period from discontinued operations	10	8,608	577
Profit for the period		**4,760**	1,094
Other comprehensive income			
Items that may be reclassified subsequently to profit and loss			
Foreign currency translation		**1,208**	(391)
Other comprehensive income for the period		**1,208**	(391)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX		**5,968**	703
-basic for net profit for half-year		4.75¢	1.09¢
-diluted for net profit for the half-year		4.75¢	1.09¢

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2012	Notes	Consolidated Dec 2012 $'000	Jun 2012 $'000
ASSETS			
Current Assets			
Cash and cash equivalents	6	**18,361**	5,193
Trade and other receivables	7	**2,373**	1,692
Income tax receivable		**-**	135
Inventories		**87**	101
Prepayments		**164**	157
		20,985	7,278
Assets classified held for sale	10	**-**	2,647
Total Current Assets		**20,985**	9,925
Non-Current Assets			
Deferred tax asset	9	**1,020**	1,596
Plant and equipment		**380**	356
Intangible assets	8	**6,668**	11,267
Total Non-Current Assets		**8,068**	13,219
TOTAL ASSETS		**29,053**	23,144
LIABILITIES			
Current Liabilities			
Trade and other payables		**1,154**	1,708
Income tax payable		**3,914**	-
Provisions		**1,257**	1,224
		6,325	2,932
Liabilities directly associated with the assets classified as held for sale	10	**-**	945
Total Current Liabilities		**6,325**	3,877
Non-Current Liabilities			
Deferred tax liabilities	9	**1,720**	3,234
Provisions		**14**	31
Total Non-Current Liabilities		**1,734**	3,265
TOTAL LIABILITIES		**8,059**	7,142
NET ASSETS		**20,994**	16,002
EQUITY			
Contributed Equity		**327**	327
Share Reserve		**199**	172
Foreign Currency Translation Reserve		**(473)**	(1,681)
Retained Earnings		**20,941**	17,184
TOTAL EQUITY		**20,994**	16,002

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

	Consolidated				
	Issued Capital	Share Reserve	Foreign Currency Translation Reserve	Retained Earnings	Total Equity
	$'000	$'000	$'000	$'000	$'000
At 1 July 2011	330	122	(1,148)	15,894	15,198
Profit for the period	-	-	-	1,094	1,094
Other comprehensive income	-	-	(391)	-	(391)
Total comprehensive income for the period	-	-	(391)	1,094	703
Transactions with owners in their capacity as owners					
Share based payment	-	15	-	-	15
Dividends	-	-	-	-	-
At 31 December 2011	330	137	(1,539)	16,988	15,916

	Issued Capital	Share Reserve	Foreign Currency Translation Reserve	Retained Earnings	Total Equity
	$'000	$'000	$'000	$'000	$'000
At 1 July 2012	327	172	(1,681)	17,184	16,002
Profit for the period	-	-	-	4,760	4,760
Other comprehensive income	-	-	1,208	-	1,208
Total comprehensive income for the period	-	-	1,208	4,760	5,968
Transactions with owners in their capacity as owners					
Share based payment	-	27	-	-	27
Dividends	-	-	-	(1,003)	(1,003)
At 31 December 2012	327	199	(473)	20,941	20,994

INTERIM CONSOLIDATED STATEMENT OF CASHFLOWS

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

	Notes	Consolidated 2012 $'000	2011 $'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		**6,403**	8,409
Payments to suppliers and employees		**(5,519)**	(4,287)
Income tax (paid)/refunded		**(153)**	(1,631)
NET CASH FLOWS FROM OPERATING ACTIVITIES		**731**	2,491
CASH FLOWS USED IN INVESTING ACTIVITIES			
Capitalised development costs		**(1,474)**	(1,660)
Interest received		**23**	20
Net inflow from sale of Amira, net of cash disposed	10	**13,883**	-
Purchase of property, plant and equipment		**(91)**	(125)
NET CASH FLOWS FROM INVESTING ACTIVITIES		**12,341**	(1,765)
CASH FLOWS FROM FINANCING ACTIVITIES			
Payment of dividends on ordinary shares	4b	**(1,003)**	-
NET CASH FLOWS FROM FINANCING ACTIVITIES		**(1,003)**	-
Net increase in cash and cash equivalents		**12,069**	726
Net foreign exchange differences		**1,099**	50
Cash and cash equivalents at beginning of period		**5,193**	3,255
CASH AND CASH EQUIVALENTS AT END OF PERIOD	6	**18,361**	4,031

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

1. Corporate Information

The interim condensed consolidated financial statements of the Group for the six months ended 31 December 2012 were authorised for issue in accordance with a resolution of directors on 22 February 2013.

Pro Medicus Limited is a company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian stock exchange.

The nature of the operations and principal activities of the Company are described in note 2.

BASIS OF PREPARATION AND ACCOUNTING POLICIES

(a) Basis of Preparation

The interim condensed consolidated financial statements for the six months ended 31 December 2012 have been prepared in accordance with AASB 134 *Interim Financial Reporting.*

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at 30 June 2012.

(b) Significant accounting policies

Apart from the changes in accounting policy noted below, accounting policies and methods of computation are the same as those adopted in the most recent annual financial statements for the year ended 30 June 2012.

(c) Changes in accounting policy

The accounting policies adopted are consistent with those of the previous financial year and there were no new standards adopted in the six month period ended 31 December 2012.

The Group has not elected to early adopt any other new Standards or amendments that are issued but not yet effective.

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

2. SEGMENT INFORMATION

The Group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team (the chief operating decision makers) in assessing performance and in determining the allocation of resources.

The operating segments are identified by management based on country of origin. Discrete financial information is reported to the executive management team on at least a monthly basis.

Types of products and services

The Group produces integrated software applications for the health care industry. In addition the Group provides services in the form of installation and support.

Accounting policies and inter-segment transactions

The accounting policies used by the Group in reporting segments internally is the same as those contained in note 1 to the accounts and in prior periods except as detailed below:

Inter-entity Sales

Inter-entity sales are recognised based on an internally set transfer price. The price aims to reflect what the business operation could achieve if they sold their output and services to external parties at arm's length.

Operating Segments

Six months ended 31 Dec 2012	Australia		Europe		North America		Total Operations	
	Dec 2012 $'000	Dec 2011 $'000	**Dec 2012 $'000**	Dec 2011 $'000	**Dec 2012 $'000**	Dec 2011 $'000	**Dec 2012 $'000**	Dec 2011 $'000
Revenue								
Sales to external customers	**2,808**	2,633	**1,640**	2,291	**1,336**	1,002	**5,784**	5,926
Inter-segment Sales	**846**	672	**1,681**	1,603	**-**	-	**2,527**	2,275
Total segment revenue	**3,654**	3,305	**3,321**	3,894	**1,336**	1,002	**8,311**	8,201
Inter-segment elimination							**(2,527)**	(2,275)
Total consolidation revenue							**5,784**	5,926
Results								
Segment Result	**(836)**	1,024	**578**	(302)	**(271)**	45	**(529)**	767
Interest Revenue							**23**	20
Non segment expenses								
Impairment Expense							**(4,600)**	-
Income Tax Expense							**1,258**	(270)
Net Profit							**(3,848)**	517

	Dec 2012 $'000	June 2012 $'000	**Dec 2012 $'000**	June 2012 $'000	**Dec 2012 $'000**	June 2012 $'000	**Dec 2012 $'000**	June 2012 $'000
Assets								
Segment Assets	**22,589**	10,706	**4,683**	6,844	**1,781**	2,947	**29,053**	20,497
Total Assets							**29,053**	20,497
Liabilities								
Segment Liabilities	**2,174**	982	**4,679**	1,171	**1,206**	4,044	**8,059**	6,197
Total Liabilities							**8,059**	6,197

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

3. REVENUE AND EXPENSES

	Consolidated	
	Dec 2012	Dec 2011
	$'000	$'000
Expenses		
Depreciation and Amortisation		
Property Improvements	**1**	1
Motor Vehicles	**2**	2
Office Equipment	**60**	55
Furniture and Fittings	**2**	3
Research & Development Equipment	**-**	4
Amortisation on computer software	**4**	58
Amortisation on capitalised development costs	**1,289**	1,554
Amortisation on intellectual property	**185**	185
Total Depreciation and Amortisation Expenses	**1,542**	1,862
Salaries and Employee Benefits Expense		
Wages & Salaries	**2,802**	2,148
Long service leave provision	**5**	-
Superannuation	**153**	133
	2,961	2,281

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

	Consolidated	
4. DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES	**2012**	2011
	$'000	$'000
(a) Dividends proposed and recognised as a liability		
Franked dividend	**-**	-
(b) Dividends paid during the half-year		
Franked dividend	**1,003**	-
(c) Dividends proposed and not recognised as a liability		
Interim Fully Franked dividend	**1,003**	501
Dividends per share (cents per share)		
-Franked dividends paid per share (cents per share)	**1.00¢**	0.50¢
-interim dividend per share	**1.00¢**	0.50¢

5. EVENTS AFTER THE BALANCE SHEET DATE

On 22 February 2013, the directors of Pro Medicus Limited declared an interim dividend of 1.0 cents per share. The total amount of the dividend is $1,002,634 which represents a fully franked dividend of a total of 1.0 cents per share. The dividend has not been provided for in the 31 December 2012 financial statements.

6. CASH AND CASH EQUIVALENTS

Reconciliation of Cash

For the purposes of the Statement of Cash Flow, cash and cash equivalents comprise the following at 31 December:

	Dec 2012	Jun 2012
	$'000	$'000
Cash at bank and in hand	**16,361**	5,140
Short term deposits	**2,000**	53
	18,361	5,193

7. TRADE AND OTHER RECEIVABLES

	Dec 2012	Jun 2012
	$'000	$'000
Trade receivables	**1,685**	1,249
Provision for impairment	**(93)**	(86)
	1,593	1,163
Research & development tax receivable	**738**	463
Other receivables	**42**	66
	2,373	1,692

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

8. INTANGIBLE ASSETS

	Intellectual Property $'000	Customer List $'000	Consolidated Development Costs $'000	Software Licenses $'000	Total $'000
Six months ended 31 December 2012					
At 1 July 2012 net of accumulated amortisation and impairment	585	21	10,642	19	11,267
Additions - internal development	-		1,500	-	1,500
Additions	-	-	-	-	-
Disposals	-	(21)	-	-	(21)
Exchange differences	-	-	-	-	-
Impairment	-	-	(4,600)	-	(4,600)
Amortisation charge for the period	(185)	-	(1,289)	(4)	(1,478)
At 31 December 2012 net of accumulated amortisation and impairment	400	-	6,253	15	6,668
At 31 December 2012					
Cost	1,847	-	14,763	252	16,862
Accumulated amortisation	(1,447)	-	(8,510)	(237)	(10,194)
Net carrying amount	400	-	6,253	15	6,668

	Intellectual Property $'000	Customer List $'000	Consolidated Development Costs $'000	Software Licenses $'000	Total $'000
Year ended 30 June 2012					
At 1 July 2011 net of accumulated amortisation and impairment	1,554	77	11,884	18	13,533
Additions - internal development	-		3,347	-	3,347
Additions	-	-	-	11	11
Disposals	-	-	-	-	-
Asset held for sale	(367)	-	(1,902)	-	(2,269)
Exchange differences	-	(3)	-	(1)	(4)
Amortisation charge for the year from a discontinued operation	(232)	-	(333)	-	(565)
Amortisation charge for the year	(370)	(53)	(2,354)	(9)	(2,786)
At 30 June 2012 net of accumulated amortisation and impairment	585	21	10,642	19	11,267
At 30 June 2012					
Cost	3,006	213	20,294	448	23,961
Asset held for sale	(367)	-	(1,902)	-	(2,269)
Accumulated amortisation	(2,054)	(192)	(7,750)	(429)	(10,425)
Net carrying amount	585	21	10,642	19	11,267

Development Costs

The Group undertook an impairment assessment of the capitalised development costs as at 31 December 2012. The recoverable amount of development costs has been determined based on a value in use calculation using cash flow projections from financial budgets approved by the Board of Directors covering a five-year period. The projected cash flows were updated to reflect the change in forecast revenues to a pay per view (operational) model and a post tax discount rate of 20% (30 June 2012:18%) was applied. Cash flows beyond a 5 year period have been extrapolated using a 2.5% growth rate (30 June 2012:2.5%). All other assumptions remained consistent with those disclosed in the annual statements for the year ended 30 June 2012. As a result of the updated analysis, the Group has recognised an impairment charge of $4,600,000 against Capitalised Development costs.

8. INTANGIBLE ASSETS (contd)

Key assumptions used in value in use calculations

The calculation of value in use for development costs is most sensitive to the following assumptions:

- Revenue forecasts
- Discount rates
- Growth rates used to extrapolate cash flows beyond the forecast period

Revenue forecasts - Revenue forecasts are based on current year consolidated budgets for each geographical segment. Estimated growth rates are then used to forecast the following four years revenue for each product used in each geographical segment. Total forecast segment growth rates range from 3% to 30% across the 4 year period.

Discount rates - Discount rates represent the current market assessment of risks specific to each cash generating unit (CGU), taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and its operating segments and is derived from its weighted average return on assets (WARA). The WARA takes into account the cost of equity from expected return on investments by the Groups investors, whilst there is no debt for the group to take into account. Specific risk is associated with the intangible asset nature and is incorporated by applying individual beta factors. The beta factors are evaluated annually.

Growth rate estimates - rates are based on industry based customer price index (CPI) forecasts. The long term rate of 2.5% was used in the current assessment.

Sensitivity to changes in assumptions

With regard to the assessment of value-in-use of development costs, the estimated recoverable amount is equal to its carrying value and, consequently, any adverse change in key assumptions could result in a further impairment loss. The key assumptions for the recoverable amount are discussed below:

Growth rate assumptions - Rates are based on management's estimated revenue forecast for the next 5 year period for each geographical segment. The revised growth rates reflect the move towards operational revenue forecast, however given the economic uncertainty, further reductions to growth estimates may be necessary in the future.

Discount rates - The discount rate has been adjusted to reflect the current market assessment of the risks specific to the intangible assets and was estimated based on the weighted average return on assets of the company. Further changes to the discount rate may be necessary in the future to reflect changing risks for the industry and changes to the weighted average return on assets. An increase in the discount rate would result in further impairment.

9. INCOME TAX

The Group calculates the period income tax expense using the tax rate that would be applicable to expected total annual earnings, i.e., the estimated average annual effective income tax rate applied to the pre-tax income of the interim period.

The major components of income tax expense in the interim consolidated income statements are:

	Dec 2012 $'000	Dec 2011 $'000
Income taxes		
Current income tax expense	**320**	552
Deferred income tax expense related to origination and reversal of deferred taxes	**938**	(28)
Income tax expense	**1,258**	524
Income tax recognised in other comprehensive income	**-**	-
Total income taxes from continuing operations	**1,258**	524

Deferred tax liabilities

	Dec 2012 $'000	Jun 2012 $'000
Foreign Currency Exchange Gain	**368**	435
Intellectual Property expenses	**(271)**	(115)
Capitalised development expenses	**1,622**	3,593
Liabilities directly associated with assets classified as held for sale	**-**	(681)
Other	**1**	2
	1,720	3,234

Deferred tax assets

Employment Entitlements	**303**	300
Tax Losses	**689**	1,274
Audit Fee Accrual	**24**	18
Other	**4**	4
	1,020	1,596

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2012

10. DISCONTINUED OPERATIONS

On 2 July 2012, the Group publicly announced the decision of its Board of Directors to sell its life sciences division of Visage Imaging, Amira. The business division of Amira is considered non-core to the operations of the Group and an offer to purchase the business was made from a French IT company, Visualization Sciences Group (VSG). The disposal of Amira was completed on 31 July 2012 for $14,134,000 in cash resulting in a pre-tax gain of $12,216,800.

The results of Amira for the period are presented below:

	Consolidated	
	Dec 2012 $'000	Dec 2011 $'000
Revenue	**327**	1,506
Cost of Goods Sold	**(4)**	(72)
Gross Profit	**323**	1,434
Operating Expenses	**(91)**	(603)
Profit/(loss) before tax from discontinued operations	**232**	831
Income tax expense	**(71)**	(254)
Profit/(loss) for the period from discontinued operations	**161**	577
Gain on disposal of the discontinued operation	**12,217**	-
Attributable tax expense	**(3,770)**	-
Profit/(loss) after tax on disposal of the discontinued operation	**8,447**	-.--
Total profit after tax for the period from a discontinued operation	**8,608**	577

Cash inflow on sale:	
Consideration received	**14,144**
Net cash disposed of with the discontinued operation	**(261)**
Net cash inflow	**13,883**

The net cash inflows/(outflows) incurred by Amira are as follows:

	Consolidated	
	Dec 2012 $'000	Dec 2011 $'000
Operating	**276**	383
Investing	**-**	(73)
Net cash inflow/(outflow)	**276**	310

Earnings/(loss) per share:		
Basic, from discontinued operations	$ 0.09	$ 0.01
Diluted, from discontinued operations	$ 0.09	$ 0.01

As Amira was sold prior to 31 December 2012, the assets and liabilities classified as part of the asset held for sale at 30 June 2012 are no longer included in the statement of financial position.

Directors' Declaration

In accordance with a resolution of the directors of Pro Medicus Limited, I state that:

In the opinion of the directors:

(a) The Financial Statements and notes of the consolidated entity are in accordance with the *Corporations Act 2001* , including:

(i) giving a true and fair view of the consolidated entity's financial position as at 31 December 2012 and of its performance for the half-year ended on that date; and

(ii) complying with Accounting Standards and the Corporations Regulations 2001

(b) There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

On behalf of the Board

P T Kempen
Chairman
Melbourne, 22 February 2013

Ernst & Young Building
8 Exhibition Street
Melbourne VIC 3000 Australia
GPO Box 67 Melbourne VIC 3001

Tel: +61 3 9288 8000
Fax: +61 3 8650 7777
www.ey.com/au

To the members of Pro Medicus Limited

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Pro Medicus Limited, which comprises the statement of financial position as at 31 December 2012, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the half-year end or from time to time during the half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal controls as the directors determine are necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of Interim and Other Financial Reports Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2012 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001* . As the auditor of Pro Medicus Limited and the entities it controlled during the half-year, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We have given to the directors of the company a written Auditor's Independence Declaration, a copy of which is included in the Directors' Report.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Pro Medicus Limited is not in accordance with the *Corporations Act 2001*, including:

a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2012 and of its performance for the half-year ended on that date; and

b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Ernst & Young

Ernst & Young

David Petersen
Partner
Melbourne
22 February 2013